Virosomal adjuvanted antigen delivery systems

References

• Gupta RK. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv Rev. 32(3), 155–172 (1998).
   PubMed Web of Science ®Google Scholar
• Thery C, Amigorena S. The cell biology of antigen presentation in dendritic cells. Curr. Opin. Immunot 13(1), 45–51 (2001).
   Google Scholar
• ••Comprehensive review of antigenpresentation mechanisms in APCs.
   Google Scholar
• Sigalq Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398(6722), 77–80 (1999).
   PubMed Web of Science ®Google Scholar
• •Experimental evidence for MHC I presentation of exogenous antigen (cross-priming).
   Google Scholar
• Mischler R, Metcalfe IC. Inflexal®V a trivalent virosome subunit influenza vaccine: production. Vaccine 20\(Suppl. 5), B17—B23 (2002).
   Google Scholar
• •Formulation of virosomes at industrial scale.
   Google Scholar
• Durrer, P, Galli C, Hoenke S et al. H.-induced membrane insertion of influenza virus hemagglutinin involves the HA2 amino-terminal fusion peptide but not the coiled coil region.' Biol. Chem. 271,13417-13421 (1996).
   Google Scholar
• Han X, Bushweller JH, Cafiso DS, Tarnm LK. Membrane structure and fusion-triggering conformational change of the fusion domain from influenza haemagglutinin. Nat. Struc. Biol. 8, 715–720 (2001).
   PubMedGoogle Scholar
• Schoen P, Leserman L, Wilschut J. Fusion of reconstituted influenza virus envelopes with liposomes mediated by streptavidin/biotin interactions. FEBS Lett. 390(3), 315–318 (1996).
   PubMed Web of Science ®Google Scholar
• Gunther-Ausbom S, Schoen P, Bartoldus I, Wilschut J, Stegmann T. Role of hemagglutinin surface density in the initial stages of influenza virus fusion: lack of evidence for cooperativity j Viral. 74(6), 2714–2720 (2000).
   Google Scholar
• Hernandez LD, Hoffman LR, Wolfsberg TG, White JM. Virus—cell and cell—cell fusion. Annu. Rev. Cell. Dev. Biol. 12, 627–661 (1996).
   PubMed Web of Science ®Google Scholar
• Weber T, Paesold G, Galli C, Mischler R, Semenza G, Brunner J. Evidence for H(.)-induced insertion of influenza hemagglutinin HA2 N-terminal segment into viral membrane.' Bid Chem. 269,18353-18358 (1994).
   Google Scholar
• Kim CU, Chen X, Mendel DB. Neurarninidase inhibitors as anti-influenza virus agents. Antivir. Chem. Chemother. 10(4), 141–154 (1999).
   Google Scholar
• Mengiardi B, Berger R, Just M, Gluck R Virosomes as carriers for combined vaccines. Vaccine 13(14),1306–1315 (1995).
   PubMed Web of Science ®Google Scholar
• ••Clinical evaluation of virosomalcombination vaccines, coformulated by crosslinking and adsorption.
   Google Scholar
• Cusi MG, Zurbriggen R, Correale Petal. Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity. Vaccine 20(29-30), 3436–3442 (2002).
   PubMed Web of Science ®Google Scholar
• Bungener L, Serre K, Bijl L et al. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 20(17-18), 2287–2295 (2002).
   PubMed Web of Science ®Google Scholar
• ••Mechanism of cytoplasmatic antigendelivery by virosomes — importance of HA compound.
   Google Scholar
• Zurbriggen R, Gluck R Irnmunogenicity of IRIV- versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Vaccine 17(11-12), 1301–1305 (1999).
   PubMed Web of Science ®Google Scholar
• Zurbriggen R, Novak-Hofer I, Seelig A, Gluck R IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization. Frog. Lipid Res. 39(1), 3–18 (2000).
   PubMed Web of Science ®Google Scholar
• •Analytical methods for the characterization of virosotnal vaccines.
   Google Scholar
• Poltl-Frank E Zurbriggen Helg, R.A et al. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine. Clin. Exp. Immunot 117(3), 496–503 (1999).
   Google Scholar
• Fehr T, Bachmann MF, Bucher E et al. Role of repetitive antigen patterns for induction of antibodies against antibodies.' Exp. Med. 185(10), 1721–1723 (1997).
   Web of Science ®Google Scholar
• Bungener L, Huckriede A, Wilschut J, Daemen T. Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs. Biosci. Rep. 22(2), 323–338 (2002).
   PubMed Web of Science ®Google Scholar
• ••Comparison of virosomes to other lipid-based delivery/adjuvant systems.
   Google Scholar
• Bungener L, Idema J, ter Veer W, Huckriede A, Daemen T, Wilschut J. Virosomes in vaccine development: induction of cytotoxic T lymphocyte activity with virosome-encapsulated protein antigens.' Liposome Res. 12(1-2), 155–163 (2002).
   Google Scholar
• Arkema A, Huckriede A, Schoen P, Wilschut J, Daemen T. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. Vaccine 18(14), 1327–1333 (2000).
   PubMed Web of Science ®Google Scholar
• •Evidence that the induction of cellular immune response depends on the presence of fusion-active HA in the virosomes.
   Google Scholar
• Rott O, Charreire J, Mignon-Godefroy K, Cash E B cell superstimulatory influenza virus activates peritoneal B cells. J. Immunol 155(1), 134–142 (1995).
   PubMed Web of Science ®Google Scholar
• Rott O, Charreire J, Semichon M, Bismuth G, Cash E B cell superstimulatory influenza virus (H2-subtype) induces B cell proliferation by a PKGactivating, Ca2.-independent mechanism. J. Immunol 154(5), 2092-2103 (1995).
   Google Scholar
• Ambrosch F, Gluck R, Herzog C, Koren A, Kollaritsch H, Wiedermann G. Antibody kinetics following the primary and the booster dose of a virosome formulated hepatitis A vaccine [abstract]. Clin. Microbial Infect. 6\(Suppl. 1), WeP306 (2000).
   Google Scholar
• Mayorga O, Egger M, Zellmeyer M, Glueck R, Herzog C, Froesner G. Efficacy of virosome formulated hepatitis A vaccine in an endemic region in Nicaragua: a randomized placebo-controlled trial. Presented at 37th ICAAC, Toronto, Canada, H4 (1997) (Abstract).
   Google Scholar
• Valentelis R, Usonis V, Bakasenas V et al Use of a virosome formulated hepatitis A vaccine in 6 to 7 month old infants and 5 to 7 year old children in Lithuania [abstract]. Clin. Microbial Infict. 6\(Suppl. 1), We08 (2000).
   Google Scholar
• Loutan L, Bovier P, Althaus B, Glueck R Inactivated virosome hepatitis A vaccine. Lancet 343,322–324 (1994).
   PubMed Web of Science ®Google Scholar
• D'Acremont V, Genton B, Glueck R, Herzog C. Use of a virosome formulated hepatitis A vaccine in adults > 50 years of age [abstract and poster]. Clin. Microbial Infect. 6\(Suppl. 1), WeP305 (2000).
   Google Scholar
• Riedemann S, Reinhardt G, Froesner GG, Gluck R, Herzog C. Universal seroconversion and low rate of side effects after one dose of the new Hepatitis A vaccine Epaxal, even when given to children less than 2 years of age. Schweiz Wochenschr. 126(Suppl. 71/I), 46S (1996).
   Google Scholar
• Holzer BR, Hatz C, Schmidt-Sissolak D, Gluck R, Althaus B, Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomised controlled trial. Vaccine 14(10), 982–986 (1996).
   PubMed Web of Science ®Google Scholar
• •Clinicial trial comparing alum-adjuvanted and virosomal vaccines.
   Google Scholar
• Bovier PA, Bock J, Loutan L, Farinelli T, Glueck R, Herzog C. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine.' Med. Viral. 68(4), 489–493 (2002).
   Web of Science ®Google Scholar
• Cryz SJ, Que JU, Gluck R A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans. Vaccine 14(14), 1381–1383 (1996).
   PubMed Web of Science ®Google Scholar
• Gluck R, Cryz J Jr. IRIV Vaccine Delivery. In: New Generation Vaccines. Levine MM, Woodrow GC, Kaper JB, Cobon IGS (Eds). Marcel Dekker Inc., NY, USA, 247–252 (1997).
   Google Scholar
• Gluck R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ Jr. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 344(8916), 160–163 (1994).
   PubMed Web of Science ®Google Scholar
• Gonne P, Gauthey L, Vernet P et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 15,1675–1679 (1997).
   PubMed Web of Science ®Google Scholar
• Pregliasco F, Mensi C, Serpilli W, Speccher L, Masella P, Belloni A. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging (Milano). 13(1), 38–43 (2001).
   Google Scholar
• Baldo V, Menegon T, Bonello C, Floreani A, Trivello R; Collaborative Group. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 19(25-26), 3472–3475 (2001).
   PubMed Web of Science ®Google Scholar
• Cusi MG, Zurbriggen R, Valassina M et al. Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity. Virology 277 (1), 111–118 (2000).
   PubMed Web of Science ®Google Scholar
• •Proof of principle for mucosal DNA delivery by virosomes.
   Google Scholar
• Correale P, Cusi MG, Sabatino M et al. Tumour-associated antigen (TAA)-specific cytotoxic T cell (ClL) response in vitro andin a mouse model, induced by TAA-plasmids delivered by influenza virosomes. Eur. Cancer. 37(16), 2097–2103 (2001).
   PubMed Web of Science ®Google Scholar
• •DNA-encoded antigen delivery by virosomes induces systemic cellular immune response against a cancer antigen.
   Google Scholar
• Waelti E, Wegmann N, Schwaninger R et al. Targeting her-2/neu with antirat Neu virosomes for cancer therapy. Cancer Res. 62(2), 437–444 (2002).
   Google Scholar
• ••Targeted virosomes for delivery of anencapsulated cytotoxic drug to cancer cells in vivo.
   Google Scholar
• Ebbert GB, Mascolo ED, Six HR Overview of vaccine manufacturing and quality assurance. In: Vaccines (Third Edition). Plotkin SA, Orenstein WA (Eds). WB Saunders Company, PA, USA, 40–46 (1999).
   Google Scholar
• Ada G. The immunology of vaccination. In: Vaccines (Third Edition). Plotkin SA, Orenstein WA (Eds). WB Saunders Company, PA, USA, 28–39 (1999).
   Google Scholar
• Hunziker IP, Grabscheid B, Zurbriggen R, Gluck R, Pichler WJ, Cerny A. In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus. Int. Immunot 14(6), 615–626 (2002).
   PubMed Web of Science ®Google Scholar
• Moreno R, Jiang L, Moehle K et al. Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design. Chembiochem. 2(11), 838–843 (2001).
   Google Scholar
• Hunziker IP, Zurbriggen R, Glueck R et al. Perspectives: towards a peptide-based vaccine against hepatitis C virus. Mol. Immunol. 38(6), 475–484 (2001).
   PubMed Web of Science ®Google Scholar